Format

Send to

Choose Destination
J Psychiatr Res. 2012 Mar;46(3):375-81. doi: 10.1016/j.jpsychires.2011.11.003. Epub 2011 Nov 26.

Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.

Author information

1
Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 1256 Briarcliff Road NE, Building A, 3rd Floor, Atlanta, GA 30306, USA. bdunlop@emory.edu

Erratum in

  • J Psychiatr Res. 2014 Jul;54:141.

Abstract

Previous studies suggest that individual preferences for medication- or psychotherapy-based treatments for depression may affect outcomes in clinical trials that compare these two forms of treatment. We assessed patients' beliefs about the causes of their depression, their preferred treatment, and strength of that preference in 80 patients participating in a 12-week clinical trial evaluating neuroimaging predictors of response to cognitive behavior therapy (CBT) or escitalopram. Forty-five patients expressed a preference for one of the 2 treatments, but being matched to preference did not influence remission or completion rates. Medication-preferring patients were more likely to terminate the trial early, regardless of treatment received. CBT-preferring patients rarely endorsed unknown causes for their depression, and medication-preferring patients were highly unlikely to identify pessimistic attitudes as a source of their depression. Among patients willing to be randomized to treatment, preference does not appear to strongly influence outcome. Specific preferences for CBT or medication may reflect differing conceptualizations about depressive illness, knowledge of which may enhance treatment retention and efficacy.

PMID:
22118808
PMCID:
PMC3288535
DOI:
10.1016/j.jpsychires.2011.11.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center